Objectives We observed previously that nebivolol treatment for 2 months reduced
cardiovascular lesions in spontaneously hypertensive rats (SHR). Therefore, we …

Nebivolol is a third-generation β-adrenergic receptor antagonist (β-blocker) with high
selectivity for β 1-adrenergic receptors. In addition, it causes vasodilatation via interaction …

Objective To obtain further insight into the mechanism underlying the vasodilator effect of
nebivolol. Since oxidative inactivation of nitric oxide (NO) is regarded as an important cause …

Background: Carvedilol is known to be an adrenoreceptor blocker and free radical
scavenger, used in hypertension and cardiac failure. However, its therapeutic actions cannot …

Arterial stiffness is a key determinant of cardiovascular risk in hypertensive patients. β-
Blockers appear to be less effective than other drugs in improving outcome in hypertensive …

Nebivolol is a vasodilating β-blocker, which can be distinguished from other β-blockers by its
haemodynamic profile. It combines β-adrenergic blocking activity with a vasodilating effect …

Nebivolol is a third-generation β-adrenoceptor antagonist. It differs from other β-
adrenoceptor antagonists as it combines highly selective β 1-adrenoceptor antagonist …

Nebivolol, compared with classical β-blockers, exerts a high selectivity for β-adrenergic
receptors and also reduces peripheral vascular resistance by modulating nitric oxide (NO) …

Objectives D/L-Nebivolol is a lypophilic β 1-adrenergic antagonist which is devoid of intrinsic
sympathomimetic activity and can increase nitric oxide (NO) bioavailability with its …

Objective: Nebivolol is a selective β 1-adrenergic receptor blocker possessing an ancillary
vasodilating effect. The objective of the present study was to study the haemodynamic and …